| Market Cap | 157.92K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -4.32M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -61.00% |
| Sales | 338.48k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -60.00% |
| Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | - | 52W High Chg | -88.00% |
| Recommedations | - | Quick Ratio | 0.00 | Shares Outstanding | 8.89B | 52W Low Chg | 100.00% |
| Insider Own | - | ROA | -26.23% | Shares Float | - | Beta | -1.77 |
| Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00020 |
| Gross Margin | -168.10% | Profit Margin | - | Avg. Volume | 62,789,507 | Target Price | - |
| Oper. Margin | -889.87% | Earnings Date | - | Volume | 496,206,029 | Change | -33.33% |
Plandaí Biotechnology, Inc. focuses on the production of proprietary botanical extracts for the nutriceutical and pharmaceutical industries. It is developing Phytofare Catechin Complex, a botanical extract derived from green tea harvested in the Senteeko Tea Estate in Mpumalanga, South Africa; and Phytofare citrus complex, a citrus extract, as well as extracts from tomato fruit, Artemisia, and cannabis. The company also produces and sells timber and agricultural products from its farm and tea estate holdings in South Africa. Plandaí Biotechnology, Inc. is based in London, the United Kingdom.
